This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Health stocks were relatively flat Thursday amid scattered clinical news, analyst actions and earnings.

Vertex Pharmaceuticals (VRTX - Get Report) was among the winners, climbing nearly 9% after the drugmaker disclosed positive interim data for a small midstage study on an investigational drug for cystic fibrosis.

The company said the results indicated a significant increase in lung function, and it will continue with its phase II trial. Shares added $1.57, or 8.8%, to $19.

Vertex is a component of the Nasdaq biotechnology index, which was up 5.87, or 0.6%, at 783.68.

Faring far worse on clinical news was small-cap SGX Pharmaceuticals (SGXP). The stock plummeted after the company said it saw dose-limiting toxicity earlier than expected in two early-stage cancer drug studies. Shares fell $2.32, or 58%, to $1.68.

Other stocks were lower after analyst actions. UBS analyst Erik Schneider initiated coverage on Omrix Biopharmaceuticals (OMRI) with a buy rating and a $17 price target, expecting strong product reception. It did little for Omrix shares, however, as the stock edged down 19 cents, or 1.4%, to $13.55.

On Wednesday, Canaccord Adams anlyst Karl Keegan downgraded Elan (ELN) to sell from hold, on economic and patent protection concerns. Shares of the Irish biotech company were down 76 cents, or 3.6%, at $20.54.

In earnings, Noven Pharmaceuticals (NOVN) lost ground after posting weaker-than-anticipated quarterly revenue. The company earned $1 million, or 4 cents a share, for the quarter ended Dec. 31, down from $7.1 million, or 29 cents per share, in the 2006 period. Excluding a $3.3 million charge, it earned 14 cents a share, matching Thomson Financial's average analyst estimate.

Revenue climbed to $23.2 million from $17.2 million, falling shy of Wall Street's expectation of $26.9 million in revenue. Noven's shares fell 76 cents, or 6.5%, to $10.66.

Corcept Therapeutics (CORT - Get Report) moved higher after its fourth-quarter report. The company posted a loss of $4.2 million, or 11 cents a share, widened from $3.9 million, or 17 cents a share, in the year-earlier period. Corcept had no revenue in the quarter, down from $73,000 in the 2006 quarter. Shares were trading up 11 cents, or 3.5%, at 3.09 on light volume.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
CORT $4.77 0.00%
VRTX $84.34 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs